Colorectal Cancer
Adventrx initiates CoFactor phase III clinical trial for metastatic colorectal cancer
Published in Drug Week, July 28th, 2006
This randomized, controlled clinical trial builds on the promising results of earlier studies, to fully investigate the efficacy and safety of CoFactor for patients with first line metastatic colorectal cancer.
Patient eligibility screening for this pivotal trial has begun at several clinical sites. A total of 100 clinical sites in the U.S. are planned for the phase III study, following institutional review board (IRB) approval of the clinical protocol, credentialing of the investigational team and an...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
Source: Drug Week (2006-07-28)
More Articles from Drug Week
- Diabetes Therapy
Exenatide improved HbA1c , weight and some cardiovascular risk factors in type 2 diabetes - Drug Delivery
Halozyme and Baxter make Hylenex available in U.S. for subcutaneous delivery of medications, fluids - Drug Development
Chimerix announces initiation of Phase I clinical trials of CMX001, an oral smallpox treatment - Insulin Resistance
Insmed presents positive Iplex data for Leprechaunism and Type A syndrome - AIDS-Related Lymphoma
HIV score, IPI score and HAART affects survival in AIDS-related non-Hodgkin lymphoma - Acute Myocardial Infarction
Alexion reports APEX-AMI study does not achieve mortality reduction in heart attack patients - More from this issue of Drug Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
